Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology
-$0.29 today
- Market cap
- $3.71B
- Beta
- 0.63
- P/E (TTM)
- -12.1
- EPS (TTM)
- -$4.39
Volume 1.30M
Average 1.16M
XENE Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Xenon Pharmaceuticals Inc.NASDAQ: XENE
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses growth accelerates
Q3 FY2026 operating expenses of $120.07M rose 522.7% year over year, ahead of the +71.7% change in trailing-twelve-month operating expenses. Sequentially, it fell 2.5% from the prior quarter. Over 3 fiscal years it compounded at +39.7% a year.
Context
- Operating expenses amounted to 5040.4% of revenue in FY2025.
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +522.7% holds above the trailing-twelve-month pace of +71.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 378.03M USD
- Year-over-year change
- +36.6%
- 4-year CAGR
- +40.3%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 378.03M | +36.6% |
| FY2024 | 2024-12-31 | 276.74M | +494.6% |
| FY2023 | 2023-12-31 | 46.54M | -66.4% |
| FY2022 | 2022-12-31 | 138.58M | +42.2% |
| FY2021 | 2021-12-31 | 97.43M | — |
Operating Expenses vs competitors
How XENE compares with its peers on the latest reported figures
- XENE's LTM Sep 2026 operating expenses of $464.71M is the 7th highest of the 11 companies compared; the peer median is $692.3M.
- Its year-over-year change of +71.7% is the 2nd highest of 11, against a peer median of +32.5%.
- Over three fiscal years its annual growth of +39.7% compares with a peer median of +14.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.31B | -18.1% | +3.6% | 70.2% | |
| LTM Sep 2026 | $2.74B | +31.1% | +21.6% | 74.0% | |
| LTM Sep 2026 | $1B | +38.7% | +6.3% | 83.2% | |
| LTM Jun 2026 | $912.58M | +33.9% | +50.1% | 117.5% | |
| LTM Jun 2026 | $844.11M | +60.9% | +8.5% | 101.6% | |
| LTM Jun 2026 | $540.5M | +1.3% | +6.6% | 14997.1% | |
| LTM Sep 2026 | $464.71M | +71.7% | +39.7% | — | |
| LTM Sep 2026 | $329.22M | +502.1% | +75.3% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $218.08M | -20.5% | +20.2% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $141.71M | +52.6% | +129.5% | 708.6% |
| LTM Dec 2025 | $44.6M | -19.1% | +0.3% | — | |
| Peer median (excluding XENE) | $692.3M | +32.5% | +14.3% | 101.6% | |
Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.44M | 9.43M | 0 | 0 | 7.5M |
| Cost of Revenue | 0 | 0 | 167.51M | 2.56M | 2.54M |
| Gross Profit | 18.44M | 9.43M | (167.51M) | (2.56M) | 4.96M |
| Gross Margin | 100.0% | 100.0% | — | — | 66.1% |
| Research & Development | 75.46M | 105.77M | 167.51M | 210.39M | 300.94M |
| Selling, General & Admin | 21.97M | 32.81M | 46.54M | 68.9M | 79.63M |
| Operating Expenses | 97.43M | 138.58M | 46.54M | 276.74M | 378.03M |
| Depreciation & Amortization | 906K | 1.41M | 3.54M | 2.56M | 2.54M |
| EBITDA | (78.09M) | (127.74M) | (210.51M) | (235.86M) | (342.35M) |
| EBITDA Margin | -423.5% | -1354.0% | — | — | -4564.7% |
| Operating Income | (78.99M) | (129.14M) | (214.05M) | (279.3M) | (373.07M) |
| Operating Margin | -428.4% | -1368.9% | — | — | -4974.3% |
| Interest Income | 466K | 8.71M | 27.62M | 41.94M | 26.83M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 105K | 3.89M | 31.37M | 40.88M | 28.18M |
| Income Before Tax | (78.89M) | (125.26M) | (182.69M) | (238.42M) | (344.89M) |
| Pre-Tax Margin | -427.9% | -1327.7% | — | — | -4598.6% |
| Income Tax Expense | (6K) | 118K | (292K) | (4.09M) | 1.02M |
| Net Income | (78.88M) | (125.37M) | (182.39M) | (234.33M) | (345.91M) |
| Net Margin | -427.8% | -1328.9% | — | — | -4612.1% |
| EPS (Basic) | (1.77) | (2.06) | (2.73) | (3.01) | (4.36) |
| EPS (Diluted) | (1.77) | (2.06) | (2.73) | (3.01) | (4.36) |
| Weighted Avg Shares | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
| Weighted Avg Shares (Diluted) | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
Intrinsic Alpha fair value
Locked
Current Price
$37.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.